IACP Complaining about FDA Letter Saying No to Office Use--Problem for IACP is Congressional Intent Does not Matter if the Face of the Statute is Clear as it is in 503A

FDA Says "No" to Office Use. FDA's letter to Representatives Griffith, Green & DeGette today clearly stated it is interpreting 503A to only permit the compounding of prescriptions for individual patients. This is in direct contradiction to Congressional intent as included in several "Statements of the Record" from Senators and Congressmen that nothing in the Drug Quality & Security Act was intended to interfere with state authority over the practice of pharmacy. Click http://bit.ly/1ph71pk to read FDA's letter.

 

FDA Says "No Office Use" to Congress - International Academy of Compounding Pharmacists

In a letter to Representatives Griffith, Green and DeGette, the Food & Drug Administration (FDA) today clearly stated it is interpreting 503A to only permit the...

iacp.site-ym.com